Jeffrey Chodakewitz

Jeffrey Chodakewitz has over two decades of experience in the pharmaceutical industry. Jeffrey began their career at Merck, where they spent four years as the Therapeutic Area Head for Infectious Diseases and Vaccines. Jeffrey then moved to Vertex Pharmaceuticals, where they served as the EVP of Clinical Medicine and External Innovation for five years. In 2014, they joined Tetraphase Pharmaceuticals as a member of the Board of Directors, and remained with the company until it was acquired by La Jolla Pharmaceuticals in 2020. Chodakewitz then served as a Member of the Board of Directors for resTORbio from 2018 to 2020, before joining Adicet Bio as an Advisor in 2021.

Jeffrey Chodakewitz earned their MD from Yale University School of Medicine and their B.S. in biochemistry from Yale University.